# GLP-1 treatment and a higher resting heart rate

Approved semaglutide labeling includes an increase in resting heart rate. Report sustained changes or a racing heartbeat at rest to the prescriber.

Canonical: https://velri.co/blog/glp1-resting-heart-rate-changes-what-provider-reviews
Publisher: Velri (https://velri.co/about)
Published: 2026-06-28
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

The approved semaglutide label describes increases in resting heart rate during treatment and calls for regular monitoring. [1]

A watch can help you notice a change. What matters next is whether it persists and whether you feel unwell.

## Resting heart rate and a recovery score are different

Resting heart rate is the number of heartbeats per minute while at rest. An app's recovery score may combine several measurements and its own calculations. When contacting the prescriber, identify the actual heart-rate reading rather than relying only on a color or score.

Useful details include the device, when the readings occurred, what your usual resting readings were and whether you felt your heart racing or pounding. Mention recent illness, vomiting, diarrhea and any new medicines too.

## A sustained change needs review

The semaglutide label advises patients to report palpitations or a racing heartbeat at rest. It directs clinicians to discontinue treatment if there is a sustained increase in resting heart rate. [1]

The label also warns that gastrointestinal symptoms can lead to dehydration. Reporting those symptoms helps the care team assess the overall situation, but it does not establish the cause of a heart-rate change by itself. [1]

## Symptoms take priority over the device

Do not wait for a wearable to confirm a problem if you feel seriously unwell. The label identifies a very rapid heartbeat alongside symptoms such as trouble breathing, swelling or fainting as a possible sign of a serious allergic reaction requiring immediate help. [1]

For an ongoing rise without emergency symptoms, send the prescriber a brief timeline and the relevant readings.

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support